These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8886913)

  • 21. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
    Sheikh M; Al-Saeed O; Kehinde EO; Sinan T; Anim JT; Ali Y
    Int Urol Nephrol; 2005; 37(4):721-6. PubMed ID: 16362587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Validity of PSA density of the transition zone in the diagnosis of prostate cancer].
    Anastasi G; Magno C; Carmignani A; Inferrera A; Petrelli A; Broccio G
    Arch Ital Urol Androl; 2000 Dec; 72(4):190-3. PubMed ID: 11221034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels.
    Horninger W; Reissigl A; Klocker H; Rogatsch H; Fink K; Strasser H; Bartsch G
    Prostate; 1998 Nov; 37(3):133-7; discussion 138-9. PubMed ID: 9792130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An artificial neural network to predict the outcome of repeat prostate biopsies.
    Remzi M; Anagnostou T; Ravery V; Zlotta A; Stephan C; Marberger M; Djavan B
    Urology; 2003 Sep; 62(3):456-60. PubMed ID: 12946746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
    Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
    Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
    Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
    Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
    Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?
    Ohori M; Dunn JK; Scardino PT
    Urology; 1995 Nov; 46(5):666-71. PubMed ID: 7495118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men.
    Lam JS; Cheung YK; Benson MC; Goluboff ET
    J Urol; 2003 Aug; 170(2 Pt 1):451-6. PubMed ID: 12853797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases.
    Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J
    Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
    Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
    J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.